Innoviva (INVA) EBITDA (2010 - 2026)
Innoviva's (INVA) quarterly EBITDA came in at $38.2 million in Q1 2026, down 7.9% YoY from $41.4 million in Q1 2025, and up 376.02% on a QoQ basis from -$13.8 million in Q4 2025.
Innoviva (INVA) EBITDA (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of EBITDA data on file, last reported at $38.2 million in Q1 2026.
- Quarterly EBITDA fell 7.9% year-over-year to $38.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $197.8 million (down 5.48% YoY) and the FY2025 annual result came in at $163.7 million, down 1.87% from the prior year.
- EBITDA advanced to $38.2 million in Q1 2026, from -$13.8 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $131.3 million in Q3 2023 to a low of -$31.3 million in Q2 2023.
- A 5-year average of $28.5 million and a median of -$6.6 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA tumbled 124.9% — and 2025, when it surged 346.51%.
- Tracing INVA's EBITDA over 5 years: stood at -$10.3 million in 2022, then jumped by 36.31% to -$6.6 million in 2023, then sank by 60.22% to -$10.5 million in 2024, then plunged by 31.16% to -$13.8 million in 2025, then jumped by 376.02% to $38.2 million in 2026.
- The last three EBITDA figures came in at $38.2 million (Q1 2026), -$13.8 million (Q4 2025), and $124.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 50.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.86 Mn |
| Mar 31, 2026 | 38.15 Mn |
| Dec 31, 2025 | -13.82 Mn |
| Sep 30, 2025 | 124.76 Mn |
| Jun 30, 2025 | 48.75 Mn |
| Mar 31, 2025 | 41.43 Mn |
| Dec 31, 2024 | -10.54 Mn |
| Sep 30, 2024 | 123.73 Mn |
| Jun 30, 2024 | 54.69 Mn |
| Mar 31, 2024 | -16.81 Mn |
| Dec 31, 2023 | -6.58 Mn |
| Sep 30, 2023 | 131.30 Mn |
| Jun 30, 2023 | -31.30 Mn |
| Mar 31, 2023 | -21.67 Mn |
| Dec 31, 2022 | -10.33 Mn |
| Sep 30, 2022 | 71.70 Mn |
| Jun 30, 2022 | -24.04 Mn |
| Mar 31, 2022 | -14.82 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | 270.58 Mn |